A decades-old unpublished study that supported use of a commonly prescribed morning sickness drug, called Diclectin, is seriously flawed, a Canadian doctor argued.
Dr. Navindra Persaud, from the department of family & community medicine at St. Michael’s Hospital in Toronto, said that the results f the study conducted in 1970s about the effectiveness of Diclectin are inconsistent.
Dr. Persaud and his team also argued that the U.S. and Canadian regulators might have overstated the benefits of the drug.
The new analysis revealed that data was missing for nearly 31 per cent of participants, and many of them dropped out before the completion of the study.
The Canadian doctor wrote, “We are trying to provide patients and doctors with access to complete and accurate information so that they can make informed decisions. This information may lead regulators like the FDA and Health Canada to revisit previous decisions.”
As the study in question was never published, it was not even subject to a scrutiny of peer review at the time.
Dr. Persaud reported his arguments in the journal PLOS ONE, a peer-reviewed, open-access journal that reports scientific studies from all disciplines.